Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects
Top Cited Papers
- 19 August 2008
- journal article
- research article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 24 (10) , 2757-2765
- https://doi.org/10.1185/03007990802361499
Abstract
(2008). Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Current Medical Research and Opinion: Vol. 24, No. 10, pp. 2757-2765. doi: 10.1185/03007990802361499Keywords
This publication has 34 references indexed in Scilit:
- Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic SurgeryClinical Pharmacokinetics, 2008
- In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxabanJournal of Thrombosis and Haemostasis, 2007
- Heart Disease and Stroke Statistics—2007 UpdateCirculation, 2007
- A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip ReplacementCirculation, 2006
- Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam studyEuropean Heart Journal, 2006
- Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacementJournal of Thrombosis and Haemostasis, 2005
- BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging studyJournal of Thrombosis and Haemostasis, 2005
- In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitorJournal of Thrombosis and Haemostasis, 2005
- The Epidemiology of Venous ThromboembolismCirculation, 2003
- Guide to Anticoagulant Therapy: HeparinArteriosclerosis, Thrombosis, and Vascular Biology, 2001